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Abstract
Background The purpose of the present study was to
determine relationship between disease activity, systemic
markers of cartilage degradation, urinary C-terminal cross-
linking telopeptides of type II collagen (uCTX-II), and
bone degradation, urinary C-terminal cross-linking
telopeptides of type I collagen (uCTX-I), structural pro-
gression of osteoarthritis (OA) and potential therapeutic
efﬁcacy of type II collagen (COLLII) in combination with
glucosamine and chondroitin sulfate (GC).
Materials and methods An observational retrospective
study, 1-year follow-up, on 104 patients with OA (nodular
osteoarthritis of the hand, erosive osteoarthritis of the hand,
EOA, osteoarthritis of the knee or hip) who were treated
with GC or glucosamine, chondroitin sulfate and collagen
type II (GCC). The following information was collected at
entry: demographics, BMI, characteristics of OA, patient
global assessment (VAS), C-terminal cross-linking
telopeptides of collagen types I (uCTX-I) and II (uCTX-II)
and radiographs. After 6 months: VAS, uCTX-I and uCTX-
II. After 1 year: VAS, uCTX-I, uCTX-II and radiographs.
Results After 6 months and 1 year of treatment VAS,
uCTX-I and uCTX-II mean values were signiﬁcantly lower
than the baseline. 57 were treated with GCC and 47 with
GC. The group that received GCC showed a similar VAS
mean value after 6 months and 1 year when compared with
the group treated with GC. uCTX-I and uCTX-II mean
level was lower in the group treated with GCC (P\0.05).
Radiological score (Kellgren and Lawrence summarized
score for hands) after 1 year showed a reduced progression
compared to the baseline in the hand osteoarthritis group,
especially after GCC treatment (P\0.05). Finally, uCTX-I
has better correlation with radiological score and with GC
in the EOA subgroup (Pearson index: R = 0.44).
Conclusions (a) uCTX-I and uCTX-II proved to be useful
biomarkers in OA monitoring; (b) uCTX-I is better corre-
lated with hand EOA and could represent a potential
further marker to assess the evolution of EOA bone dam-
age; (c) GC slow down OA progression; (d) ﬁnally COLLII
could represent a further protective factor in OA cartilage.
Keywords Osteoarthritis  Type II collagen  Cartilage 
uCTX-I  uCTX-II
Introduction
Articular cartilage is constructed with hyaline cartilage
tissue. It is composed of chondrocytes located in lacunae
and in the extracellular matrix. The chondral matrix con-
tains water, collagen, proteoglycans, non-collagenous
matrix proteins and lipids. Articular cartilage is divided
into four zones—superﬁcial, intermediate, deep and calci-
ﬁed—according to morphology, the orientation of collagen
ﬁber, and the proteoglycan content. The dominant collagen
of this tissue is type II collagen (COLLII), together with
smaller quantities of other collagens (IX, XII). Numerous
studies have shown that chondrocytes also have tissue-
speciﬁc antigens, which induce the introduction of anti-
bodies in patients with cartilage grafts, as well as those
with osteoarthritis (OA) [1].
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drocytes can have migratory capacity, and the migratory
ones can synthesize COLLII but not type I collagen
(COLLI) [2]; this can be interpreted as further evidence
that joint damage involves mostly COLLII.
Collagens are a big family of proteins, the main one
forming connective tissue in all higher animals. Connective
tissues contain a mixture of cells, proteins, complex poly-
saccharides and inorganic constituents. COLLII, like
elastine and proteoglycans, is located in the extracellular
matrix and is produced by ﬁbroblasts.
The functional property of COLLII is to give strength
and ﬂexibility to the connective tissue, resisting the ten-
sions suffered in the direction of its ﬁbers. At the moment
there are 28 different identiﬁed types of collagen. In con-
nective tissue, native COLLII is arranged in ﬁbrils. Its
function consists in giving strength and ﬂexibility to the
connective tissue, resisting the tensions suffered in the
direction of its ﬁbers. Also, COLLII is present in joints. It
has a special conﬁguration that gives particular elastic
properties to protein: collagen ﬁbers are located in the
extracellular matrix and have the capacity to increase or
reduce their volume according to the degree of compres-
sion to which they are subjected. Therefore it protects the
organs and tissues from rupture and loss of form or struc-
ture when they are stressed by sudden or violent
movements. Besides its structural role in tissues and
organs, collagen is also important for the development of
tissues, one of its functions is to inﬂuence the differentia-
tion and proliferation of non-specialized cells. Over the last
years numerous molecular markers of cartilage breakdown
have been used and evaluated to predict the structural
progression of OA. Among the used markers, one of the
most reliable resulted urinary C-terminal cross-linking te-
lopeptides of type II collagen (uCTX-II) [3–11]. COLLI is
a metalloprotease cleavage product of human articular
cartilage and is normally used to test osteoclastic activity
and to quantify bone reabsorption [10]. The article aims at
providing a comparison between two associations (gluco-
samine–chondroitin sulfate and glucosamine–chondroitin
sulfate–native COLLII partially hydrolyzed) in a cohort of
Italian patients with OA. Furthermore, the role of urinary
C-terminal cross-linking telopeptides of type I collagen
(uCTX-I) and uCTX-II as biomarkers has been evaluated.
Materials and methods
Patients and methods
This was an observational retrospective 1-year follow-up
study. This study has considered patients who came to our
hospital between October 2006 and October 2007 and who
were affected by osteoarthritis of the hand, hip or knee
(fulﬁlling the American College of Rheumatology Criteria)
[12].
At baseline the following characteristics were collected:
age, gender, BMI. Each patient was evaluated at baseline,
after 6 months and after 1 year with a general rheumato-
logic assessment, a patient global assessment (0–100 mm
VAS), uCTX-I and uCTX-II measurement.
For the urinary evaluation of degradation products of
C-terminal telopeptides of Type I human collagen the
Urine CrossLaps
 ELISA Kit has been employed and for
products of C-terminal telopeptides of type II the Urine
CartiLaps
 ELISA kit (both from Nordic Bioscience
Diagnostic—DK, Italian subsidiary Pantec—Turin) has
been employed. The method gives a quantitative determi-
nation employing a competitive enzyme immunosorbent
assay on micro-titer wells by using urine from second
morning void, the concentration is referred to the creatinine
excretion with results as nanogram/mmol of creatinine.
At baseline and after 1 year a radiological evaluation of
hands, hip or knee as needed was observed. All radiographs
were evaluated by two experienced rheumatologists and
the Kellgren and Lawrence score was used [13]. Obviously,
patients whose required parameters were (partially) absent
from our archives were not considered. Secondary OA, due
for example to fracture, inﬂammatory diseases (such as
rheumatoid arthritis) or Paget disease, was an exclusion
criterion. Patients with current corticosteroid therapy and/
or anti-osteoporotic drugs and/or renal or hepatic dys-
function in the year before onset of the study were
excluded too.
Hundred and four patients were thus included in the
study (95 females, 9 males), mean age was
61.4 ± 7.2 years. Thirty patients were affected by hand
EOA, 54 by hand OA and 20 distributed between knee or
hip OA.
Forty-seven were treated with glucosamine
1,000 mg + chondroitin sulfate 1,000 mg (GC) and 57
with glucosamine 1,000 mg + chondroitin sulfate
1,000 mg + native COLLII partially hydrolyzed 2 mg
(GCC).
The study was performed in accordance to the
Declaration of Helsinki.
Statistical analysis
Continuous variables were analyzed in terms of
mean ± standard deviation.
Standard Student’s t-test for paired samples or one-way
ANOVA were performed for comparing data, as needed. A
P-value\0.05 has been valued as signiﬁcant.
All analyses were carried out with SPSS software for
windows Ver 13.0.
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Analyzing the whole population, VAS (Fig. 1) was reduced
signiﬁcantly after 6 months (t1: P = 0.014), and was still
low after 1 year (t2: P = 0.004) compared to the baseline
(t0) in both groups (GC and GCC). The same is true for
uCTX-1 (Fig. 2), t1: P = 0.001 and t2: P = 0.002. There
was no signiﬁcant difference between GC and GCC.
uCTX-I in hand OA and hand EOA is more reduced in the
group treated with GCC at t2 (P = 0.026) compared to the
other group (Fig. 3).
Urinary C-terminal cross-linking telopeptides of type I
collagen in the EOA subgroup is more signiﬁcantly
reduced (P = 0.017) at t2 with GCC compared to GC
(Fig. 4).
Urinary C-terminal cross-linking telopeptides of type I
collagen has a higher baseline in the EOA subgroup.
Urinary C-terminal cross-linking telopeptides of type II
collagen is signiﬁcantly reduced in the whole population
both at t1 (P = 0.003) and t2 (P = 0.002) and with both
treatments (Fig. 5); patients treated with GCC improve
more quickly and steadily over 1 year, whereas patients
treated with GC show smaller improvements which tend to
regress at t2.
To make a more accurate comparison of the uCTX-II
improvements, we chose the group affected by hand
Fig. 1 VAS in the whole population (GC + GCC)
Fig. 2 Urinary C-terminal cross-linking telopeptides of type I
collagen in whole population (GCC + GC)
Fig. 3 Urinary C-terminal cross-linking telopeptides of type I
collagen in hand OA and hand EOA, GCC vs. GC
Fig. 4 Urinary C-terminal cross-linking telopeptides of type I
collagen in EOA group, GCC vs. GC
J Orthopaed Traumatol (2008) 9:81–87 83
123arthritis (OA + EOA) because it is the more numerous and
homogeneous from many points of view (sex, age, BMI).
uCTX-II is signiﬁcantly reduced at t1 (P = 0.01) already,
with both treatments. However, at t2 (P = 0.017) patients
treated with GCC show further improvements whereas
patients treated with GC tend to regress (Fig. 6).
From the radiological point of view, in the hand arthritis
group (OA + EOA), patients with GCC show a decrease in
the bone decay rate over 1 year (P = 0.009) (Fig. 7),
starting from similar radiologic score at t0. Figure 8 is like
Fig. 7, but limited to patients with hand-EOA (P = 0.018),
starting with similar radiologic score at t0, as well.
In EOA patients, analyzing the possible correlation
between radiological data, uCTX-I and uCTX-II, we found
a signiﬁcant correlation between radiological score (at t2)
and uCTX-I (both at t1 and t2), with a Pearson index
R = 0.59, P = 0.0008.
There is no correlation between radiological data and
uCTX-II.
In hand OA patients, there is a weak correlation between
radiological data and uCTX-II, with a Pearson index
Fig. 5 Urinary C-terminal cross-linking telopeptides of type II
collagen in whole population (GCC + GC)
Fig. 6 Urinary C-terminal cross-linking telopeptides of type II
collagen in hand OA and hand EOA, GCC vs. GC
Fig. 7 Evolution of radiological score in hand OA and hand EOA,
GC vs. GCC
Fig. 8 Evolution of radiological score in hand EOA, GC vs. GCC
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the EOA group is better described by uCTX-I than uCTX-
II.
Pearson index between radiological score and uCTX-I
in the EOA group treated with GC is R = 0.44. Pearson
index between radiological score and uCTX-I in the EOA
group treated with GCC is R = 0.12. This datum is
consistent with the fact that GCC slows down the rate of
increase of radiological score, thus uCTX-I is a better
indicator of radiological evolution in the GC group
compared to the GCC group, where the effect of the drug
weakens the correlation between these two variables
(Fig. 9).
Discussion
OA is the most common and frequent of the rheumatic
diseases. Research on pathogenesis has suggested new
ideas both in new diagnostic tests and in therapy.
Our study, in accordance with many AA, has conﬁrmed
the validity of uCTX-II in the diagnosis and quantitative
analysis of cartilage breakdown [10, 11] also during follow
up, independently of area, localization and histological
grading of affected joints [14] and atrophic or hypertrophic
patterns of OA [7].
In our study, also uCTX-I has demonstrated itself
interesting. Recently, as a matter of fact, the presence of
bone resorption has been recognized as a risk factor for OA
progression. A recent study [15] demonstrated that general
bone resorption, indicated by serum biomarker measure-
ments, is increased in patients with progressive knee OA.
These results conﬁrmed the role of bone changes in the
pathogenesis of OA. It is generally believed that
degeneration of cartilage in OA is characterized by two
phases: a biosynthetic phase during which the cells resident
in cartilage, the chondrocytes, attempt to repair the dam-
aged extracellular matrix; and a degradation phase, in
which the activity of enzymes produced by the chondro-
cytes digests the matrix, matrix synthesis is inhibited, and
the consequent erosion of the cartilage is accelerated. The
cellular reaction pattern during the osteoarthritic disease
process is at ﬁrst glance rather heterogeneous. However,
the reaction patterns can basically be summarized in ﬁve
categories: (a) proliferation and cell death (apoptosis), (b)
changes in synthetic activity, (c) changes in degradation,
(d) phenotypic modulation of the articular chondrocytes,
and (e) formation of osteophyte. Several factors such as
retinoic acid, bromodeoxyuridine and IL-1, induce
so-called ‘‘dedifferentiation’’ or modulation of the chondro-
cytes phenotype to a ﬁbroblast-like phenotype. The
chondrocytes stop expressing aggrecan and collagen type
II, though they are still very active cells and express
collagen types I, III and V [16]. Some AA [17] have
reviewed the evidence that OA abnormal osteoblasts are
responsible: (a) to maintain the abnormal mineralization,
(b) to release factors that can modify both osteoblasts and
chondrocytes functions and (c) to degrade articular carti-
lage. OA osteoblasts release more IL-6, CXCL12,
CXCL13 and leptin that can also directly modulate COLLI
synthesis, promote articular cartilage degradation and
contribute to inﬂammatory state observed in OA. Produc-
tion of an abnormal collagen matrix and a soluble factor(s)
by OA osteoblasts leads to an abnormal osteoid matrix not
mineralizing normally. This putative factor(s) contributes
to cartilage degradation but also to abnormal osteoblasts
cell function, measurable also as uCTX-I. Marcelli et al.
[18] underline the relationship between hand OA and bone
mineral density and Zoli et al. [19] conﬁrm it also in hand
EOA, a destructive form of primary OA. The most
important problem for therapy is the large pathogenetic
process number. Obviously therapeutic intervention in
order to control both joint cartilage collagen content and
bone content have to be considered in OA management.
Numerous pharmaceutical and nutriceutical agents [20]
have been developed and are used also in combination, to
improve the efﬁcacy in delaying the progression of struc-
tural changes in OA cartilage [21, 22]. Actually many AA
have described the efﬁcacy and potential disease-modify-
ing effect of glucosamine, chondroitin sulfate, avocado
soybean unsaponiﬁables, diacerhein, intraarticular hyalu-
ronan, ginger, doxycycline, ascorbic acid, manganese,
growth factors [23].
Our group wanted to test the potential capacity of native
COLLII, partially hydrolyzed, in association with GC, to
lessen the damage and progression of OA, based on the
above. Collagen gives bone its ﬂexibility, helping it to
Fig. 9 Correlation between radiological score (abscissa) and uCTX-I
(ordinate) in hand EOA, GC vs. GCC
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123resist tension. COLLII helps to promote new cartilage
synthesis and reduces oxidative damage to the joints. In our
study a synergic mix of natural compounds, as GCC,
worked together to reduce both articular and bone OA
damage.
Our data demonstrated that a substance which is
probably able to interfere on cartilage catabolism, to help
the promotion of new cartilage synthesis and to reduce
oxidative damage to the joint, like native COLLII
partially hydrolyzed, could represent a further new ther-
apeutic possibility to improve hand OA, even in
association with other SYSADOAs (Symptomatic slow
acting drugs for osteoarthritis). Trentham has speciﬁed
that several studies have shown signiﬁcant improvement
in symptoms when patients were supplemented with
undenatured COLLII, including improved joint mobility
and ﬂexibility, reduced joint pain, and, in some patients,
complete remission of symptoms. The fact that OA is
often characterized by an underlying immune disorder
lends itself to likelihood that an immune-enhancing
nutrient such as undenatured COLLII could be useful in
reducing inﬂammation and redness symptoms of OA, as
well [24]. Bagchi et al. conﬁrm the efﬁcacy of undena-
tured COLLII in OA and RA in a pilot study in humans
[25]. D’Altilio et al. in a placebo-controlled study dem-
onstrated that daily treatment of arthritis-affected dogs
with COLLII alone or in combination with GC markedly
alleviates arthritis-associated pain and is well tolerated as
no side effect was noted [26].
Moreover, evidence of the better uCTX-I correlation in
the EOA subgroup, even considering the smaller case
record, could suggest that EOA might have greater afﬁnity
with metabolic bone diseases, like osteoporosis [27, 28].
Further studies are necessary to conﬁrm the efﬁcacy of
COLLII as a protective factor of OA cartilage, and the
potential signiﬁcance of uCTX-I as a further marker to
assess the evolution of EOA bone damage.
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